Results of a phase 1/2 study of sacituzumab tirumotecan in patients with unresectable locally advanced or metastatic solid tumors refractory to standard therapies
Related Posts
Riely GJ, Ahn MJ, Clarke JM, Dagogo-Jack I, Esper R, Felip E, Gelsomino F, Goldman JW, Hussein M, Johnson M, Marrone KA, Morgensztern D, Nadal[...]
Jonas BA, Fisch SC, Curtin PT, Schiller GJ, Jeyakumar D, Tzachanis D, Bejar R, Qi L, Wieduwilt MJ, Tuscano JM, Damon L, Logan AC; University[...]
Cabanski CR, Yang E, Stewart MD, Allen JD, Connolly JE, Dugan U, Greenberg PD, Mackall CL, June CH, Marson A, Maus MV, Ribas A. Intentional[...]